Larsen & Toubro Ltd.'s share price jumped over 6% on Thursday, following the company’s steady quarterly earnings report and encouraging forecasts from brokerages.
For the September quarter, L&T reported a 20% year-on-year increase in revenue, reaching Rs 61,554 crore, which aligned with market expectations. Operating profit rose by 13% to Rs 6,632 crore, although the Ebitda margin contracted slightly by 70 basis points to 10.33%. Net profit also saw a 7% increase, totaling Rs 4,113 crore.
Brokerages responded positively to L&T's performance, reinforcing their bullish outlook on the stock. Jefferies maintained a 'buy' rating, setting a target price of Rs 4,160 per share, which suggests a potential upside of 23%. The brokerage highlighted the significant growth in L&T’s engineering and construction margins, noting a 84% year-on-year increase in international execution, despite modest domestic order flow.
Nomura also has a 'buy' rating with a target price of Rs 4,100 per share, citing a favourable risk-reward profile supported by solid international order inflows and a manageable domestic pipeline. Bernstein maintained an 'outperform' rating, emphasising L&T's resilience in managing working capital amid global uncertainties.
Emkay has set an even more optimistic target of Rs 4,300, indicating a 26.2% potential upside, driven by an upward revision in its fiscal 2026-27 earnings forecast. Nuvama also echoed this sentiment, with a target price of Rs 4,000 apiece, noting that L&T's second quarter results exceeded market expectations, aided by strong year-on-year execution growth and stable core operating margins.
Also Read: L&T Q2 Results Review: Strong International Orders, Revenue Growth Offset Margin Pressures
Larsen & Toubro Share Price Today
The scrip rose as much as 6.49% to 3,629.65 apiece. It pared some gains to trade 6.47% higher at Rs 3,628.95 apiece, as of 09:51 a.m., compared to a 0.22% decline in the NSE Nifty 50.
It has risen 22.55% in the last 12 months. Total traded volume so far in the day stood at 7.6 times its 30-day average. The relative strength index was at 57.
Out of 35 analysts tracking the company, 30 maintain a 'buy' rating, four recommend a 'hold' and one suggests 'sell', according to Bloomberg data. The average 12-month analysts' consensus price target implies an upside of 12.6%.
RECOMMENDED FOR YOU

Sensex 2025-End Target To Be Hiked? HSBC's Herald Van Der Linde Bullish On India's Growth Story—Top Picks


Festive Sales Set To Soar As Centre Pushes For Early GST Rate Cut Rollout


Stock Calls Today: IT, Auto, NBFCs On Brokerages' Radar


Gland Pharma Share Price Surges Over 6% As Jefferies Upgrades Ratings, Hikes Target Price Post Q1 Results
